Please assess the completion status of the following clinical trial:

Trial Title: A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria~* Biopsy proven aggressive non-hodgkin's lymphoma~  * Follicular center lymphoma Grade 3.~ * Diffuse large B-cell lymphoma.~ * Mantle cell lymphoma.~ * Transformed lymphoma.~* Relapsed or refractory to previous therapy for lymphoma~* At least one prior combination chemotherapy regime~* Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter~* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2~* Willing to follow the pregnancy precautions~Key Exclusion criteria~* Any of the following laboratory abnormalities.~  * Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5\*10\^9/L).~ * Platelet count \< 60,000/mm\^3 (60\*10\^9/L).~ * Calculated creatinine clearance of \<50mL/min~ * Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times upper limit of normal (ULN).~ * Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)/conjugated bilirubin \>0.8mg/dL.~* Subjects who are candidates for and willing to undergo an autologous stem cell transplant.~* History of active Central Nervous System (CNS) lymphoma within the previous 6 months~* History of other malignancies within the past year~* Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lenalidomide (Type: EXPERIMENTAL): 25 mg oral lenalidomide once daily on Days 1-21 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).